3Plunker W, Liliemark JO, Adams TM. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res, 1987,47:3005.
4Kucera GL, Capizzi RL. 1-β-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylytransferase.Cancer Res, 1992,52 : 3886.
5Kharbanda S,Emoto Y,Kisaki H. 1-β-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Mol Pharmacol, 1994,46:67.
6Emoto Y, Kisaki H, Manome Y. Activation of protein kinase Cδ in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood, 1996,87 : 1990.
7Gunji H,Kharbanda S,Kufe D. Induction of intemucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res, 1991,51 :741.
8Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997,89 : 1845.
9Cassileth PA, Lynch E, Hines JD. Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 1992,79 : 1924.
10Weick JK, Kopecky KJ, Appelbaum FR.Randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia:a southwest oncology group study. Blood,1996,88:2841.
5Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014;371(16):1507-1517.
6Peters JM, Preston-Martin S, London S J, et al. Processed meats and risk of childhood leukemia (California, USA). Cancer Causes Control. 1994;5(2):195-202.
7Schemhammer ES, Bertrand KA, Birmann BM, et al. Consumption of artificial sweetener- and sugar-containing soda and risk of lymphoma and leukemia in men and women. Am J Clin Nutr. 2012;96(6):1419-1428.
8Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
9Lo-Coco F, Awisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-121.
10Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-884.
